Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service tumor ablation cases in Maryland: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 15% on average (83 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 4 | 197 | 14% |
| 2020 | 3 | 168 | 15% |
| 2021 | 1 | 190 | 19% |
| 2022 | 4 | 193 | 22% |
| 2023 | 5 | 233 | 25% |
| 2024 | 5 | 276 | 28% |
| 2025 from claims | – | 415 336–488 | 29% |
| 2026 forecast | – | 463 363–582 | 29% |
| 2027 forecast | – | 509 377–672 | 29% |
| 2028 forecast | – | 558 395–770 | 30% |
| 2029 forecast | – | 613 416–878 | 31% |
| 2030 forecast | – | 672 440–998 | 31% |
Percutaneous liver, kidney, lung, and bone tumor ablation. Professional codes (what the surgeon bills): CPT 47382, 47383, 50592, 50593, 32998, 20982, 20983.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Maryland; 4 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 3 | 795+1.4%/yr | +1.4%/yr | 0.4 | 0% | 1,250 in 2030+7.8%/yr |
| Texas | 6 | 772−0.3%/yr | −0.3%/yr | 0.4 | 0% | 1,010 in 2030+4.6%/yr |
| Georgia | 2 | 335+1.7%/yr | +1.7%/yr | 0.4 | 0% | 260 in 2030−3.9%/yr |
| North Carolina | 3 | 334−1.9%/yr | −1.9%/yr | 0.3 | 0% | 320 in 2030−0.8%/yr |
| Virginia | 1 | 278+2.6%/yr | +2.6%/yr | 0.3 | 0% | 470 in 2030+9%/yr |
| South Carolina | 2 | 220−0.1%/yr | −0.1%/yr | 0.3 | 0% | 260 in 2030+3.1%/yr |
| Tennessee | 3 | 213+0.5%/yr | +0.5%/yr | 0.3 | 0% | 280 in 2030+4.6%/yr |
| Louisiana | 0 | 112+4%/yr | +4%/yr | 0.3 | 0% | 290 in 2030+17%/yr |
| Alabama | 0 | 110+2.3%/yr | +2.3%/yr | 0.3 | 0% | 140 in 2030+4.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Breast biopsy & localization | 79 | 5,089−2.2%/yr | −2.2%/yr | 6.00.9× | 73% | 5,630 in 2030+1.7%/yr |
| Tumor & fibroid embolization | 12 | 701+17%/yr | +17%/yr | 0.81.4× | 80% | 1,270 in 2030+10%/yr |
Tumor ablation in every state, and its device makers · Every procedure market in Maryland · Every state · Compare with Florida
Pulse Biosciences leads with 69% of company spending on these surgeons in 2025, +64 pts on 2024.
In 2025, 19 companies reported engagement with Maryland’s surgeons worth $916K in consulting, speaking, meals and travel tied to these products, about $183K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 5 recalled product lines (3 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.